The Inflation Reduction Act (IRA) temporarily extended Affordable Care Act premium subsidies and instituted an insulin co-pay cap for Medicare beneficiaries, but bipartisan agreement is needed to make these changes permanent and more broadly applicable, explained A. Mark Fendrick, MD.
The Inflation Reduction Act (IRA) temporarily extended Affordable Care Act (ACA) premium subsidies and instituted an insulin co-pay cap for Medicare beneficiaries, but bipartisan agreement is needed to make these changes permanent and more broadly applicable, explained A. Mark Fendrick, MD, co–editor in chief of The American Journal of Managed Care® and director of the Center for Value-Based Insurance Design at the University of Michigan.
Transcript
The IRA extended ACA premium subsidies another 3 years. Do you think subsidies may continue to be extended?
Well, you'd like to think that making insurance coverage more affordable would be popular and not partisan. But unfortunately, just about everything in the United States—from baseball to space exploration—has turned out to be partisan, in addition to health care. So, while it's certainly better than not extending these subsidies, to extend them for 3 years, it wouldn't surprise me to have this issue come to fore quite quickly, and it wouldn't surprise most of the listeners to understand that one party will support strengthening the Affordable Care Act and continuing its legacy and others may not be as interested.
The IRA was a pared-down version of the Build Back Better Act, which had several proposals to reform the ACA. Do you see a future life for any of those that did not make it into the IRA?
One of the more important proposals, and one that fell just 3 Republican senators’ votes short, was the application of an insulin co-pay cap of $35 a month in the commercial marketplace. We're very pleased and excited to know that this same policy was passed as part of the Medicare program. So now, people who require insulin will not have to pay exorbitant amounts of money out of pocket to get this potentially lifesaving drug.
It has been stated by Majority Leader [Chuck] Schumer [D-New York] that there will be a return to vote on the insulin co-pay cap in the commercial marketplace after the midterm elections. And I'm hopeful that Congress will act prudently and wisely and pass this extremely important policy that will impact people to use a potentially lifesaving drug for which, in my opinion, there is really no overuse.
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Traditional Medicare Supplemental Insurance and the Rise of Medicare Advantage
May 7th 2024Rising Medicare Advantage enrollment occurred alongside declines in enrollment in traditional Medicare with employer-sponsored supplemental coverage and traditional Medicare without supplemental coverage.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen